Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
August 12, 2021 07:00 ET
|
Ocuphire Pharma
Continued Momentum in Nyxol® Programs with Announcement of Positive Top-Line Results from VEGA-1 Phase 2 Trial in Presbyopia Nyxol plus Low-Dose Pilocarpine Phase 2 Trial Results Show Potential for...
Ocuphire Pharma Presenting at Two Conferences in August
August 06, 2021 07:30 ET
|
Ocuphire Pharma
Canaccord Genuity 41st Annual Growth Conference being held virtually on August 10-12, 2021 HC Wainwright Ophthalmology Virtual Conference on August 17, 2021 FARMINGTON HILLS, Mich., Aug. 06,...
Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease
July 22, 2021 08:00 ET
|
Ocuphire Pharma
Highlights Favorable Safety Profile of the Oral New Chemical Entity APX3330 and Its Novel Anti-Angiogenic and Anti-Inflammatory Mechanism of Action Properties Relevant to a Broad Range of Retinal...
Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July
July 13, 2021 09:00 ET
|
Ocuphire Pharma
Positive Results from Phase 2 Presbyopia (VEGA-1) and Phase 3 Reversal of Mydriasis (MIRA-2) Studies to be Presented at 2021 ASCRS Annual Meeting in Las Vegas Ocuphire Presenting Nyxol® + Low Dose...
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 09, 2021 17:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., July 09, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely...
Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints
June 30, 2021 07:15 ET
|
Ocuphire Pharma
Met primary endpoint with statistical significance at 1 hour with 61% of subjects treated with Nyxol® plus low-dose pilocarpine (LDP) gaining ≥ 15 letters (3 lines) in near vision Key secondary...
Ocuphire Announces Addition to the Russell Microcap® Index
June 11, 2021 07:30 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., June 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on development and commercialization of...
Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market
June 08, 2021 16:10 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., June 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on development and commercialization of...
Ocuphire Announces Appointment of Jay S. Pepose, M.D., Ph.D. to Its Board of Directors
June 08, 2021 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., June 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 04, 2021 09:04 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., June 04, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...